Acquisition - June 18, 2020
Novo Nordisk to acquire Corvidia Therapeutics
Novo Nordisk has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Corvidia Therapeutics’ lead candidate, ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6), is being developed to reduce the risk of major adverse […]
Acquisition - June 7, 2020
Potential merger between AstraZeneca and Gilead
AstraZeneca has made a preliminary approach to Gilead Sciences about a potential merger, according to Bloomberg. AstraZeneca informally contacted Gilead last month to gauge its interest in a possible tie-up asking not to be identified because the details are private, reports Bloomberg. AstraZeneca didn’t specify terms for any transaction, they said. No decisions have been […]
Acquisition - May 20, 2020
Agrisera acquired by Olink
Vännäs-based Agrisera has been acquired by Uppsala based biotech company Olink Proteomics. Agrisera is specializing in the production of polyclonal and monoclonal antibodies. The company provides a large range of ready-made antibodies, mainly for plant research, which are used, for example, to better understand photosynthesis. It also provides reagents and secondary antibodies, as well as […]
Acquisition - May 19, 2020
Elekta acquires Kaiku Health
Elekta will further develop its focus on cancer care providers and their patients through its acquisition of Finnish company Kaiku Health. Kaiku is best known for its app that monitors patient-reported outcomes, providing intelligent symptom tracking and management for healthcare providers in routine oncology care and studies. The Kaiku Health app screens for patients’ symptoms, […]
Acquisition - March 23, 2020
Lipigon acquires antisense drug candidates
Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna. The company has acquired antisense drug candidates jointly generated with Secarna Pharmaceuticals under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a […]
Acquisition - February 25, 2020
AstraZeneca divests global rights to Movantik to RedHill Biopharma
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope […]
